Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update

Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a large decline in short interest in July. As of July 31st, there was short interest totalling 270,600 shares, a decline of 19.6% from the July 15th total of 336,600 shares. Based on an average daily trading volume, of 451,500 shares, the short-interest ratio is presently 0.6 days. Approximately 0.4% of the shares of the stock are sold short.

Insider Buying and Selling

In other Atyr PHARMA news, Director Paul Schimmel bought 52,300 shares of the business's stock in a transaction on Wednesday, July 24th. The stock was bought at an average price of $1.93 per share, for a total transaction of $100,939.00. Following the completion of the transaction, the director now owns 413,023 shares in the company, valued at approximately $797,134.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.70% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on ATYR. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Thursday. Royal Bank of Canada reiterated an "outperform" rating and set a $16.00 price objective on shares of Atyr PHARMA in a research report on Wednesday.

Atyr PHARMA Stock Down 4.5 %

NASDAQ ATYR traded down $0.09 during mid-day trading on Friday, reaching $1.91. 796,039 shares of the stock were exchanged, compared to its average volume of 482,658. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07. The firm has a market cap of $131.81 million, a P/E ratio of -2.12 and a beta of 1.25. Atyr PHARMA has a 1-year low of $1.08 and a 1-year high of $2.50.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.01. As a group, sell-side analysts anticipate that Atyr PHARMA will post -0.89 earnings per share for the current year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.